Erythropoietin-induced recurrent veno-occlusive priapism associated with end-stage renal disease.
This is the first report of a male hemodialysis patient experiencing recurrent dialysis-associated priapism that resolved when his concurrent erythropoietin dose was reduced from 2000 to 1500 U one time per week and held if his hemoglobin was greater than 10 g/dL. We discuss dialysis-associated priapism and the effects of erythropoietin on the coagulation cascade and male hormone levels in an effort to elucidate the etiology of priapism in this patient.
Department of Urology, Mayo Clinic, Rochester, Minnesota 55901, USA.
J A
JA
Brown
A
A
Nehra
D000328:Adult; D004921:Erythropoietin / Q000009:adverse effects*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy*; D008297:Male; D011317:Priapism / Q000209:etiology*; D012008:Recurrence; D006435:Renal Dialysis / Q000009:adverse effects*
D004921:Erythropoietin